ストックスクリーナーアプリを入手
5.28
3.53%
0.18
アフターアワーズ：
5.31
0.03
+0.57%
前日終値:
$5.10
開ける：
$5.22
24時間の取引高:
3.02M
Relative Volume:
0.70
時価総額：
$823.18M
収益：
$2.80M
当期純損益:
$-115.18M
株価収益率:
-6.2316
EPS:
-0.8473
ネットキャッシュフロー:
$-94.03M
1週間 パフォーマンス:
+14.04%
1か月 パフォーマンス:
+34.01%
6か月 パフォーマンス:
+70.87%
1年 パフォーマンス:
+98.50%
1日の値動き範囲:
$5.16
$5.48
1週間の範囲:
$4.66
$5.48
52週間の値動き範囲:
$2.24
$6.72
Absci Corp Stock (ABSI) Company Profile
Compare ABSI vs VRTX, REGN, ARGX, ALNY, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ABSI
Absci Corp
|
5.28 | 795.12M | 2.80M | -115.18M | -94.03M | -0.8473 |
VRTX
Vertex Pharmaceuticals Inc
|
435.93 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.62 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.43 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Absci Corp Stock (ABSI) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-01-08 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2025-10-02 | 開始されました | JP Morgan | Overweight |
| 2025-07-03 | 再開されました | Morgan Stanley | Overweight |
| 2025-01-22 | 開始されました | Needham | Buy |
| 2024-10-02 | 開始されました | Guggenheim | Buy |
| 2024-07-03 | 開始されました | Morgan Stanley | Overweight |
| 2024-03-14 | 開始されました | Scotiabank | Sector Outperform |
| 2023-12-05 | 開始されました | KeyBanc Capital Markets | Overweight |
| 2023-05-04 | 開始されました | H.C. Wainwright | Buy |
| 2022-08-12 | ダウングレード | JP Morgan | Overweight → Underweight |
| 2022-07-18 | 開始されました | Truist | Buy |
| 2022-03-02 | 再開されました | Cowen | Market Perform |
| 2022-02-01 | 開始されました | Berenberg | Buy |
| 2021-11-10 | ダウングレード | BofA Securities | Neutral → Underperform |
| 2021-10-15 | 再開されました | Cowen | Market Perform |
| 2021-08-16 | 開始されました | BofA Securities | Neutral |
| 2021-08-16 | 開始されました | Cowen | Market Perform |
| 2021-08-16 | 開始されました | Credit Suisse | Outperform |
| 2021-08-16 | 開始されました | Stifel | Hold |
すべてを表示
Absci Corp (ABSI) 最新ニュース
CRISPR Therapeutics Has Major Catalysts Ahead. Is This Biotech Stock a Screaming Buy? - AOL.com
The 1 AI Stock I'd Put in a Time Capsule and Open in 2036 - AOL.com
Grail's Slump Enters Week 10. Is There Any End in Sight? - AOL.com
Doximity Stock Just Got Crushed. Is This a Rare Chance to Buy a High-Quality Growth Company on Sale? - AOL.com
JonesTrading Maintains Absci Corp(ABSI.US) With Buy Rating, Maintains Target Price $11 - Moomoo
2 Stocks That Could Realistically Double by 2030 - AOL.com
ABSI Price Today: Absci Corporation Stock Price, Quote & Chart | MEXC - MEXC Exchange
Absci Insider Buyers Pleased With US$700k Return On Investment - Yahoo Finance
AI-driven drug developer Absci lines up Jefferies and Goldman talks - Stock Titan
Portland InnoAbsci's move into generative AI | Why former Hydro Flask CEO joined Puffin - The Business Journals
Morgan Stanley Trims Price Target on Absci to $4.10 From $4.20, Keeps Equalweight Rating - Moomoo
AMD Reveals A $6.5 Million Marvell Bet That's Already Soaring - Sahm
Insider Buying: Menelas Pangalos Acquires Shares in Absci Corp (ABSI) - GuruFocus
Absci Corp (ABSI) director Menelas Pangalos adds 37,453 shares in open-market buy - Stock Titan
AMD Reveals A $6.5 Million Marvell Bet That's Already Soaring - Benzinga
HC Wainwright Has Optimistic Outlook of Absci Q3 Earnings - MarketBeat
Absci price target raised to $11 from $9 at JonesResearch - TipRanks
TradingKey - TradingKey
JonesTrading Maintains Absci Corp(ABSI.US) With Buy Rating, Raises Target Price to $11 - 富途牛牛
Earnings call transcript: Absci Corp misses revenue forecast in Q1 2026 - Investing.com UK
H.C. Wainwright Maintains Absci Corp(ABSI.US) With Buy Rating, Maintains Target Price $8 - Moomoo
Absci Corporation (ABSI) reports Q1 loss, misses revenue estimates - MSN
Absci Corp. Charts High-Stakes Path With ABS-201 - TipRanks
Needham Reiterates Buy Rating on ABSI with Price Target of $7.00 - GuruFocus
Needham Maintains Absci Corp(ABSI.US) With Buy Rating, Maintains Target Price $7 - Moomoo
Absci (NASDAQ:ABSI) Given New $11.00 Price Target at Truist Financial - MarketBeat
Absci’s ABS-201 Hair-Loss Trial Moves Forward: What Early-Stage Data Could Mean for ABSI - TipRanks
Absci (NASDAQ:ABSI) Shares Gap DownShould You Sell? - MarketBeat
Absci Shares Fall After 1Q Loss Widens - Moomoo
Truist Financial Maintains Absci Corp(ABSI.US) With Buy Rating, Announces Target Price $11 - 富途牛牛
Absci Corporation (NASDAQ:ABSI) Q1 2026 Earnings Call Transcript - Insider Monkey
12 Health Care Stocks Moving In Friday's Pre-Market SessionAbsci (NASDAQ:ABSI), Amylyx Pharmaceuticals - Benzinga
Absci Reports Business Updates and First Quarter 2026 Financial and Operating Results - The Manila Times
TD Cowen Maintains Absci Corp(ABSI.US) With Buy Rating - 富途牛牛
Absci (NASDAQ:ABSI) Releases Quarterly Earnings Results, Hits Estimates - MarketBeat
Absci reports Q1 EPS (19c), consensus (20c) - TipRanks
Earnings call transcript: Absci’s Q1 2026 revenue falls short, stock dips - Investing.com Nigeria
Absci Corporation (ABSI) Reports Q1 Loss, Misses Revenue Estimates - Yahoo Finance
Earnings call transcript: Absci’s Q1 2026 revenue falls short, stock dips By Investing.com - Investing.com South Africa
Absci Corp (NASDAQ:ABSI) Plunges on 86% Q1 Revenue Miss Despite Clinical Advances - ChartMill
Absci Q1 Earnings Call Highlights - Yahoo Finance
Hair-loss drug trial reaches patient dosing; Absci adds ABS-202 - Stock Titan
Absci (ABSI) posts Q1 2026 results, advances ABS-201 and adds ABS-202 - Stock Titan
Absci (NASDAQ: ABSI) Q1 loss widens as revenue falls to $0.2M - Stock Titan
Absci : Corporate Presentation, May 2026 - marketscreener.com
Absci (ABSI) Q1 2026 Earnings Call Transcript - The Globe and Mail
Absci Corp (ABSI) 財務データ
収益
当期純利益
現金流量
EPS
Absci Corp (ABSI) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Busch Andreas | Chief Innovation Officer |
Mar 12 '26 |
Buy |
2.29 |
100,000 |
229,000 |
421,446 |
| Pangalos Menelas N | Director |
Feb 27 '26 |
Buy |
2.74 |
75,095 |
205,760 |
189,055 |
| McClain Sean | Chief Executive Officer |
Feb 23 '26 |
Option Exercise |
1.21 |
396,399 |
479,643 |
8,730,966 |
| McClain Sean | Chief Executive Officer |
Feb 02 '26 |
Sale |
2.99 |
26,761 |
80,015 |
8,334,567 |
| Jonasson Zachariah | CFO / CBO |
Feb 02 '26 |
Sale |
2.99 |
17,496 |
52,313 |
383,538 |
| VAN HOUTEN FRANS | Director |
Dec 05 '25 |
Buy |
3.72 |
40,000 |
148,800 |
63,320 |
| Pangalos Menelas N | Director |
Sep 22 '25 |
Buy |
2.66 |
95,785 |
254,788 |
113,960 |
| Bedrick Todd | SVP, CAO |
Sep 22 '25 |
Buy |
2.70 |
10,000 |
27,000 |
180,428 |
| Busch Andreas | Chief Innovation Officer |
Jul 28 '25 |
Buy |
3.04 |
50,000 |
152,000 |
327,264 |
0.98%
0.12%
大文字化:
|
ボリューム (24 時間):